Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.